A Phase IIa, two-part, randomised, multi-centre, multinational, double-blind, placebo-controlled, parallel group study to compare the efficacy and safety of BCT197 when added on to standard of care for the treatment of acute respiratory exacerbations o

Project: Other project

StatusFinished
Effective start/end date6/15/166/14/18

Funding

  • ICON Clinical Research LLC: $8,126.93